Market Context — Why This Technology, Why Now

The global medical device market is experiencing robust growth, driven by an aging demographic and increasing prevalence of chronic diseases. Regulatory bodies are also tightening requirements for device safety and long-term performance, pushing manufacturers to seek advanced biocompatible materials. This technology directly addresses these pressures by offering a solution that could significantly reduce adverse biological reactions, thereby enhancing patient outcomes and extending device lifespan, crucial for competitive differentiation.

Key Competitive Advantages
01

Provides multi-faceted coagulation inhibition: Offers a polymer compound that multi-laterally suppresses the activation of coagulation, complement, and platelet systems in vivo, achieving broader biocompatibility improvement compared to conventional single-approach methods.

02

Establishes high technological uniqueness: With only 3 prior art documents, this technology demonstrates high originality, enabling early market advantage and competitive differentiation.

03

Enables broad application potential: The polymer compound, featuring specific ether-containing repeating units, could be applied to diverse medical devices and biomaterials, enhancing existing product performance and accelerating new product development.

Market Opportunity
Medical Devices and Materials
$15B–$25B globally (AI est.)
The aging global population and rising chronic diseases like heart and kidney conditions are driving increased demand for medical devices such as catheters, artificial dialysis membranes, and artificial blood vessels. This trend elevates the importance of highly biocompatible materials.
Global medical device manufacturers Cardiovascular implant developers Dialysis equipment suppliers Biomaterial coating specialists
Regenerative Medicine and Tissue Engineering
$5B–$6B globally (AI est.)
In regenerative medicine and cell therapy, safe and stable scaffold materials and cell culture substrates are crucial for in-vivo function. This technology could optimize cell interaction, contributing to maximized therapeutic effects.
Regenerative medicine startups Cell therapy developers Tissue engineering material suppliers Biopharmaceutical research firms
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a specific polymer compound structure designed to suppress the activation of coagulation, complement, and platelet systems in vivo. It has overcome two office actions, indicating robust technical grounds and a broad scope of claims, making it highly defensible against invalidation challenges.

Competitive White Space

This patent primarily covers the polymer compound and its compositions. White space exists in developing novel device designs that leverage this material, advanced drug delivery systems integrating the polymer, or specialized manufacturing processes for its application.

Economic Impact
~$650K/year estimated medical cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Complications from medical device-related thrombosis and foreign body reactions lead to additional treatments, extended hospital stays, and increased nursing costs. Assuming 1,000 complications annually, each incurring an average additional cost of ~$3,350 (AI est.), this technology could reduce 20% of these costs, resulting in an estimated annual saving of ~$650K (AI est.). Indirect benefits include reduced healthcare worker burden and improved equipment utilization.

Speed to Market
6× faster than in-house development
This technology clearly defines a specific polymer compound, its compositions, and medical device applications. The fundamental polymer structure and mechanism of action are concretely defined within the patent, significantly shortening the time from proof-of-concept to product launch compared to new development. Primarily a material application, it could be relatively easy to integrate into existing manufacturing processes, accelerating product development cycles and enabling early market entry.
Competitive Positioning

X: Multi-faceted Biocompatibility
Y: Coagulation and Platelet Inhibition

Business Models & Applications
🏥 Material Supply for Medical Devices
Supply this polymer compound as a material for existing medical devices like catheters, artificial organs, and diagnostic probes. This model enhances product value by improving biocompatibility and reducing thrombosis risk.
🧪 High-Performance Coating Agent Development
Develop a biocompatible coating agent based on this technology for surgical instruments and extracorporeal circulation circuits. This solution enhances safety and reliability in clinical settings.
🧬 Regenerative Medicine and Pharmaceutical Applications
Apply this polymer compound as a cell culture scaffold material or drug delivery system carrier in regenerative medicine. This provides a highly biocompatible foundation, accelerating R&D.
Adjacent Application Opportunities
💉 Diagnostics and In Vitro Testing
Application in In Vitro Diagnostics
Leveraging its coagulation-inhibiting properties, this technology could be applied to in vitro diagnostic devices like blood bags, blood separation filters, and diagnostic probes. It has the potential to enhance blood sample stability, improving testing accuracy and reducing contamination risks by up to 15%.
👓 Ophthalmology and Orthopedics
Enhancing Implant Biocompatibility
Application to implantable products such as contact lenses, intraocular lenses, and artificial joints is promising. Coating surfaces with this polymer compound could enhance biocompatibility, potentially reducing inflammatory responses and foreign body sensation by 20-30% for improved patient comfort.
💊 Pharmaceuticals and Biotechnology
Biopharmaceutical Containers and Process Materials
This technology could be applied to containers and tubing used for biopharmaceutical manufacturing and storage. It is expected to inhibit protein adsorption and aggregation, improving drug quality stability and reducing product loss by up to 10%, thereby contributing to cost savings for high-value biopharmaceuticals.
Integration Roadmap — Estimated 18-Month Deployment
Phase 1: Technology Evaluation and Material Compatibility
Duration: 3 months
Evaluate the detailed properties of this polymer compound material and verify its compatibility with target medical device products. Conduct initial benchmark testing and gather safety data.
Phase 2: Prototype Development and Performance Assessment
Duration: 6 months
Integrate this polymer material into selected medical device products to manufacture prototypes. Conduct detailed performance evaluations, including biocompatibility, coagulation inhibition, and physical stability, to confirm product viability.
Phase 3: Manufacturing Process Establishment and Market Entry
Duration: 9 months
Based on evaluation results, establish the manufacturing process and finalize adjustments for mass production. Prepare for necessary regulatory approvals and clinical trials, and formulate market introduction and deployment strategies.
Technical Feasibility
This technology targets specific polymer compounds, their compositions, and medical device applications. The patented polymer, featuring side chains with ether structures linked by ether bonds, is highly compatible with existing organic material synthesis and polymer processing technologies. This provides a technical foundation for integration as a material without significant changes to current manufacturing lines.
Success Scenario
Implementing this technology could significantly reduce the risk of thrombus formation in medical devices such as catheters and artificial lungs. This is expected to decrease patient complication rates by up to 20%, reducing the need for re-hospitalization and additional treatments. Consequently, it could contribute to improved patient quality of life and enhanced efficiency in clinical settings.
Patent Record
APPLICATION NO.
特願2012-194391
REGISTRATION NO.
6195335
FILING DATE
2012年09月04日
GRANT DATE
2017年08月25日
EXPIRATION DATE
2032年09月04日
PATENT HOLDER
国立大学法人山形大学
Examination History
2015年09月02日
出願審査請求書
2016年05月17日
拒絶理由通知書
2016年09月16日
意見書
2016年09月16日
手続補正書（自発・内容）
2017年01月17日
拒絶理由通知書
2017年03月14日
意見書
2017年08月01日
特許査定